Showing 131-140 of 4046 results for "".
Talking to Patients: Men v. Women
https://practicaldermatology.com/topics/practice-management/talking-to-patients-men-v-women/18693/Every patient is unique, but aesthetic physicians may need to tailor their communication style based on the patient's sex. It's also essential to convey to men that you understand the male aesthetic and how their treatment goals may differ from the typical woman's.Vitiligo Update: Pathogenesis, Therapies, and Integrative Approaches
https://practicaldermatology.com/issues/may-june-2025/vitiligo-update-pathogenesis-therapies-and-integrative-approaches/35920/Vitiligo is a chronic autoimmune condition characterized by depigmented white patches due to melanocyte destruction, attributed to genetic factors and environmental triggers.Patient Growth Made Easy: Smart Strategies for Mature Cosmetic Practices
https://practicaldermatology.com/issues/july-2025/patient-growth-made-easy-smart-strategies-for-mature-cosmetic-practices/36510/You know your practice’s identity. You have honed your mission, vision, and values. Your practice is established, and your dream team is in place. What is the next step to take in attracting and keeping new patients?FDA Approves Roflumilast for Seborrheic Dermatitis in Young Patients
https://practicaldermatology.com/topics/other-dermatitis/fda-approves-roflumilast-for-seborrheic-dermatitis-in-young-patients/20230/Patrick Burnett, MD, PhD, chief medical officer of Arcutis Biotherapeutics, talks with Practical Dermatology® about the first new treatment for seborrheic dermatitis in more than 20 years, their newly approved ZORYVE (roflumilast)Topical Foam, 0.3% for use in patients aged 9 years or older.Guselkumab in PsA: Exploring Patient-Reported Outcomes in Real-World Settings
https://practicaldermatology.com/topics/psoriasis/guselkumab-in-psa-exploring-patient-reported-outcomes-in-real-world-settings/20226/Philip Mease, MD, shares new real-world data showing that psoriatic arthritis patients who take Tremfya (guselkumab) report meaningful improvements in pain, physical function, and fatigue through six months.Patient Experience with PDT
https://practicaldermatology.com/series/pdt-in-practice/patient-experience-pdt/28863/Dr. Joel L. Cohen discusses how he implemented photodynamic therapy and describes the patient experience with it, including scheduling considerations.Increasing Patient Compliance with the Right Vehicles
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/increasing-patient-compliance-with-the-right-vehicles/18877/Peter Lio, MD and Elaine Siegfried, MD talk about their vehicles of choice to enhance patient adherence to treatment, especially when treating scalp psoriasis. They also discuss how packaging innovations have led to vehicle innovations.Educating Patients On OTC Products
https://practicaldermatology.com/topics/practice-management/educating-patients-on-otc-products/19023/Kristina Goldenberg, MD describes how to incorporate patient education into care, particularly the importance of addressing patient misconceptions regarding OTC products.Advanced Live Patient Workshop on Fillers: NASHA
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/advanced-live-patient-workshop-on-fillers-nasha/19392/LIVE Patient DemonstrationsDr. Ross on Therapeutic and Warning Endpoints for Laser Therapy in Skin of Color Patients
https://practicaldermatology.com/topics/skin-of-color/dr-ross-on-therapeutic-and-warning-endpoints-for-laser-therapy-in-skin-of-color-patients/28657/E. Victor Ross, MD, discusses his presentations at the Skin of Color Update, where he addressed ways to enhance using laser therapy in practice on patients with skin of color.